Exploring the therapeutic potential of TRAIL in diabetes and the metabolic syndrome

探索 TRAIL 在糖尿病和代谢综合征中的治疗潜力

• 批准号: nhmrc : 1027911
• 负责人: Dr Christos Tikellis
• 金额: $ 29.76万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/exploring-therapeutic-potential-metabolic-syndrome/110604
• 关键词: Exploring; therapeutic; potential; TRAIL; diabetes

TNF-related apoptosis-inducing ligand (TRAIL) is a protein with potentially useful actions in human health and disease. TRAIL is able to prevent atherosclerosis, the cause of heart attacks and strokes. In addition, we have recently shown that its actions on fat and the pancreas may prevent the development of the metabolic syndrome and type 2 diabetes. These studies will explore the therapeutic potential of TRAIL for the prevention of diabetes and heart disease in a range of animal models.

肿瘤坏死因子相关的凋亡诱导配体(TRAIL)是一种在人类健康和疾病中具有潜在作用的蛋白质。TRAIL能够预防动脉粥样硬化，动脉粥样硬化是心脏病发作和中风的原因。此外，我们最近表明，它对脂肪和胰腺的作用可能会防止代谢综合征和2型糖尿病的发展。这些研究将探索TRAIL在一系列动物模型中预防糖尿病和心脏病的治疗潜力。